Enanta Pharmaceuticals, Inc.

ENTA · Nasdaq · United States

Share price · ENTA

$8.23-5.07 (-38.12%) 3M

close as of 2026-11-18 · 24h delayed · vol 812K (3.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ENTA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-18.6%
  2. 6 Nov 2026+9.1%

    Nothing announced by ENTA that day or the session before.

  3. 28 Oct 2026-5.2%
  4. 28 Sep 2026+6.2%

    Nothing announced by ENTA that day or the session before.

  5. 24 Aug 2026+4.7%

    Nothing announced by ENTA that day or the session before.

  6. 16 Jun 2026+5.5%

    Nothing announced by ENTA that day or the session before.

  7. 15 Jun 2026-3.9%

    Nothing announced by ENTA that day or the session before.

  8. 3 Jun 2026-6.6%

    Nothing announced by ENTA that day or the session before.

  9. 12 May 2026-6.0%
  10. 5 Mar 2026-10.8%

    Nothing announced by ENTA that day or the session before.

Share of unusual movement by asset

For each asset, the share of ENTA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
zelicapavir
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—55%
Other company news (earnings, financing, releases naming no asset)—8%
Sessions with no dated event—37%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2
RSV L proteinSmall molecule
Respiratory Syncytial Virus Infection
Phase 2
RSV N protein (nucleoprotein)Small molecule
Respiratory Syncytial Virus Infection

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
zelicapavirPhase 2RSV Infection, RSV, Respiratory Syncytial Virus (RSV)
Est. primary completion 2026-12 · NCT07482657 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
zelicapavirPhase 2/3RSV
Est. primary completion 2029-07 · NCT07908381 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 September 2025Topline resultzelicapavirPhase 2b RSVHR of zelicapavir: no effect on the primary symptom endpoint; key secondary virology endpoints met
Enanta Pharmaceuticals, Inc. · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$14M$22M$33M+ $156M short-term inv.$20M-$10.0M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$17M$19M$35M+ $129M short-term inv.$13M-$7.2M operating cash flowreport ↗
2025-Q4$19M$21M$37M+ $148M short-term inv.$12M-$12M operating cash flowreport ↗
2025-Q2$18M$27M$45M+ $159M short-term inv.$18M$18M operating cash flowreport ↗
2025-Q1$15M$28M$60M+ $133M short-term inv.$23M-$13M operating cash flowreport ↗
2024-Q4$17M$28M$84M+ $132M short-term inv.$22M-$17M operating cash flowreport ↗
2024-Q2$18M$29M$36M+ $194M short-term inv.$23M-$15M operating cash flowreport ↗
2024-Q1$17M$36M$64M+ $237M short-term inv.$31M-$29M operating cash flowreport ↗
2023-Q4$18M$36M$40M+ $297M short-term inv.$33M-$25M operating cash flowreport ↗
2023-Q2$19M$43M$95M+ $291M short-term inv.$39M-$32M operating cash flowreport ↗
2023-Q1$18M$43M$73M+ $137M short-term inv.$38M-$14M operating cash flowreport ↗
2022-Q4$24M$41M$42M+ $172M short-term inv.$29M-$36M operating cash flowreport ↗
2022-Q2$19M$39M$28M+ $225M short-term inv.$32M-$30M operating cash flowreport ↗
2022-Q1$19M$42M$41M+ $239M short-term inv.$34M-$26M operating cash flowreport ↗
2021-Q4$28M$49M$99M+ $160M short-term inv.$30M-$13M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$65M$107M$32M+ $157M short-term inv.$20M-$19M operating cash flowreport ↗

Enanta Pharmaceuticals reported fiscal 2025 revenue of $65.32M, down 3.4% YoY, and R&D spend of $106.74M, down 18.8% YoY. It ended the year with cash and equivalents of $32.3M and cash, cash equivalents and marketable securities of $188.9M, with a net loss of $81.89M ($3.84 per diluted share) for the twelve months ended September 30, 2025.

Management guided that existing cash, retained royalty cash flows, and proceeds from the October 2025 upsized public offering (approximately $74.8M gross) are expected to fund operations into fiscal 2029. During the period, Enanta reported positive topline data from the Phase 2b RSVHR study of zelicapavir, nominated EPS-3903 as its lead oral STAT6 inhibitor candidate, and selected EDP-978 as an oral KIT inhibitor candidate, with IND filings planned for the first quarter of 2026 and the second half of 2026, respectively. The company also filed a patent infringement action against Pfizer in the European Unified Patent Court regarding Paxlovid.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$68M$131M$37M+ $211M short-term inv.$29M-$79M operating cash flowreport ↗
2023-FY$79M$164M$85M+ $285M short-term inv.$33M-$103M operating cash flowreport ↗
2022-FY$86M$165M$44M+ $205M short-term inv.$30M-$85M operating cash flowreport ↗
2021-FY$97M$174M$57M+ $187M short-term inv.$20M-$70M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 9 sales ($183K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-08Rottinghaus Scott T. · Chief Medical OfficerTax withholding1,467$13.34$20KForm 4
2026-03-11CARTER BRUCE L A · directorAward / grant (derivative)20,000——Form 4
2026-03-11FOLETTA MARK G · directorAward / grant (derivative)20,000——Form 4
2026-03-11Hata Yujiro S · directorAward / grant (derivative)20,000——Form 4
2026-03-11Peterson Kristine · directorAward / grant (derivative)20,000——Form 4
2026-03-11Russell Lesley · directorAward / grant (derivative)20,000——Form 4
2026-03-11Vance Terry · directorAward / grant (derivative)20,000——Form 4
2026-02-12Luly Jay R. · director, President and CEOAward / grant4,800——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 132 reporting institutions held 26.8M shares ($290.3M).

#InstitutionSharesValue
1JANUS HENDERSON GROUP PLC3,784,055$47.7M
2BlackRock, Inc.3,103,768$39.2M
3FARALLON CAPITAL MANAGEMENT LLC2,871,862$36.3M
4Deep Track Capital, LP1,956,867$24.7M
5VANGUARD CAPITAL MANAGEMENT LLC1,178,049$14.9M
6VANGUARD PORTFOLIO MANAGEMENT LLC948,904$12.0M
7Spruce Street Capital LP932,598$11.8M
8MILLENNIUM MANAGEMENT LLC882,097$11.1M
9GEODE CAPITAL MANAGEMENT, LLC725,061$9.2M
10RENAISSANCE TECHNOLOGIES LLC665,258$8.4M
11STATE STREET CORP562,106$7.1M
12Hillsdale Investment Management Inc.435,510$5.5M
13AQR CAPITAL MANAGEMENT LLC313,157$4.0M
14MORGAN STANLEY309,511$3.9M
15CHARLES SCHWAB INVESTMENT MANAGEMENT INC294,971$3.7M